Krzysztof W Selmaj
Overview
Explore the profile of Krzysztof W Selmaj including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
3868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Siwek T, Zwiernik B, Jezierska-Wozniak K, Jezierska K, Mycko M, Selmaj K
Front Neurol
. 2024 Feb;
15:1345503.
PMID: 38370525
Background And Objectives: X-linked adrenomyeloneuropathy (AMN) is an inherited neurodegenerative disorder associated with mutations in the ABCD1 gene and the accumulation of very long-chain fatty acids (VLFCAs) in plasma and...
2.
Dubinsky M, Charles L, Selmaj K, Comi G, Krakovich A, Rosen M, et al.
Inflamm Bowel Dis
. 2024 Jan;
30(12):2512-2515.
PMID: 38267826
No abstract available.
3.
Naismith R, Cohen J, Bar-Or A, Comi G, Selmaj K, Hartung H, et al.
Mult Scler
. 2023 Dec;
30(2):177-183.
PMID: 38130041
Background: Monoamine oxidase (MAO) inhibitors can interact with selective serotonin reuptake inhibitors (SSRIs)/serotonin-norepinephrine reuptake inhibitors (SNRIs). There is clinical interest surrounding use of ozanimod with SSRIs/SNRIs because the major metabolites...
4.
Dayan C, Lecumberri B, Muller I, Ganesananthan S, Hunter S, Selmaj K, et al.
Mult Scler J Exp Transl Clin
. 2023 Jan;
9(1):20552173221142741.
PMID: 36619856
Background: Alemtuzumab is an effective therapy for relapsing multiple sclerosis. Autoimmune thyroid events are a common adverse event. Objective: Describe endocrine and multiple sclerosis outcomes over 6 years for alemtuzumab-treated...
5.
Cree B, Selmaj K, Steinman L, Comi G, Bar-Or A, Arnold D, et al.
Mult Scler
. 2022 Jun;
28(12):1944-1962.
PMID: 35765217
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for treatment of relapsing forms of MS. Objective: To characterize long-term safety and efficacy...
6.
Mycko M, Zurawska A, Selmaj I, Selmaj K
Front Immunol
. 2022 Jun;
13:875994.
PMID: 35720271
Circular RNA (circRNA) molecules represent a novel and unique class of endogenous non-coding RNAs controlling the expression and function of microRNA (miRNA) and post-transcriptional regulation. Recent studies implicated circRNA in...
7.
Selmaj K, Mycko M, Furlan R, Rejdak K
Curr Opin Neurol
. 2022 Jun;
35(3):286-292.
PMID: 35674070
Purpose Of Review: Multiple sclerosis (MS) is highly heterogenic disorder with respect to clinical course, diagnosis, and treatment response. There is an urgent need to search for simply and reliable...
8.
Zurawska A, Mycko M, Selmaj I, Raine C, Selmaj K
Neurol Neuroimmunol Neuroinflamm
. 2021 Aug;
8(5).
PMID: 34385287
Background And Objectives: To investigate the total circular RNA (circRNA) profile in patients with relapsing-remitting multiple sclerosis (RRMS) and healthy controls (HCs). Methods: Hybridization microarray was used to define the...
9.
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Coles A, Arnold D, Bass A, Boster A, Compston D, Fernandez O, et al.
Ther Adv Neurol Disord
. 2021 May;
14:1756286420982134.
PMID: 34035833
Background: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly...
10.
Selmaj K, Cohen J, Comi G, Bar-Or A, Arnold D, Steinman L, et al.
Mult Scler Relat Disord
. 2021 Apr;
51:102844.
PMID: 33892317
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for the treatment of relapsing multiple sclerosis (RMS). In phase 3 trials, ozanimod was...